Search results
Results from the WOW.Com Content Network
Low IGF-1 levels are shown to increase the risk of developing type 2 diabetes and insulin resistance. [67] On the other hand, a high IGF-1 bioavailability in people with diabetes may delay or prevent diabetes-associated complications, as it improves impaired small blood vessel function. [67] IGF-1 has been characterized as an insulin sensitizer ...
The IGF-1 receptor is the "physiological" receptor. IGF-1 binds to it at significantly higher affinity than it binds the insulin receptor. Like the insulin receptor, the IGF-1 receptor is a receptor tyrosine kinase—meaning the receptor signals by causing the addition of a phosphate molecule on particular tyrosines. The IGF-2 receptor only ...
Download as PDF; Printable version; In other projects Wikidata item; ... Insulin-like growth factor 1 receptor (IGF-1R) Insulin-like growth factor 2 receptor (IGF-2R ...
AKT can have a number of downstream effects such as activating CREB, [2] inhibiting p27, [3] localizing FOXO in the cytoplasm, [3] activating PtdIns-3ps, [4] and activating mTOR [3] which can affect transcription of p70 or 4EBP1. [3] There are many known factors that enhance the PI3K/AKT pathway including EGF, [5] shh, [2] IGF-1, [2] insulin ...
IGF-2 exerts its effects by binding to the IGF-1 receptor and to the short isoform of the insulin receptor (IR-A or exon 11-). [9] IGF-2 may also bind to the IGF-2 receptor (also called the cation-independent mannose 6-phosphate receptor), which acts as a signalling antagonist; that is, to prevent IGF-2 responses.
Approximately 98% of IGF-1 is always bound to one of six binding proteins (IGF-BP). IGFBP-3, the most abundant protein, accounts for 80% of all IGF binding. IGF-1 binds to IGFBP-3 in a 1:1 molar ratio. IGF-BP also binds to IGF-1 inside the liver, allowing growth hormone to continuously act upon the liver to produce more IGF-1.
Mecasermin, sold under the brand name Increlex, also known as recombinant human insulin-like growth factor-1 (rhIGF-1), is a recombinant form of human insulin-like growth factor 1 (IGF-I) which is used in the long-term treatment of growth failure and short stature in children with severe primary IGF-I deficiency, for instance due to growth hormone deficiency or Laron syndrome (growth hormone ...
The hypothalamic–pituitary–somatotropic axis (HPS axis), or hypothalamic–pituitary–somatic axis, also known as the hypothalamic–pituitary–growth axis, is a hypothalamic–pituitary axis which includes the secretion of growth hormone (GH; somatotropin) from the somatotropes of the pituitary gland into the circulation and the subsequent stimulation of insulin-like growth factor 1 ...